TAK-500

About Takeda

Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.

About Thermo Fisher Scientific

Thermo Fisher Scientific's mission is to enable its customers to make the world healthier, cleaner, and safer by providing the scientific tools and services that accelerate innovation. The company has achieved a dominant market position through strategic acquisitions, organic innovation, and the creation of an unparalleled, integrated ecosystem for the scientific community. Its strategy revolves around leveraging its scale and breadth to drive operational excellence, investing in high-growth areas like bioproduction and precision medicine, and selectively advancing an internal pipeline of novel therapeutics. With a market capitalization exceeding $178 billion, Thermo Fisher is a foundational pillar of the global life sciences industry.

Therapeutic Areas

Other Solid Tumors Drugs